AXGN vs BAC Stock Comparison

AXGN currently leads BAC in this stock comparison, with AIQ scores of 65 vs 56. The clearest difference is momentum, while BAC has the stronger value profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 9 points
AXGN
Healthcare
vs
BAC
Financial Services
AXGN
AxoGen, Inc.
Leads
Price
$56.95
Day move
+2.85%
AIQ Score
65/100
Best edge
Momentum
Sector
Healthcare
BAC
Bank of America Corporation
Price
$48.91
Day move
-1.07%
AIQ Score
56/100
Best edge
Value
Sector
Financial Services

What is the main difference between AXGN and BAC?

AXGN leads the current stock comparison as AxoGen, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

AxoGen, Inc. vs Bank of America Corporation

Data as of Nov 18, 2026· market close· Cross-sector · Healthcare vs Financial Services· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 4/10

AXGN leads

AXGN leads by 9 AIQ points, primarily on Momentum and Quality, having only recently taken the lead back from BAC. Wall Street currently favors BAC on target upside.

Fragile: 3 of 6 evidence groups support AXGN, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Reversed
AXGN

AxoGen, Inc.

Leads
AIQ Score
65/100
AIQ Edge Score
7/10
BAC

Bank of America Corporation

AIQ Score
56/100
AIQ Edge Score
6/10

The Algovestiq AIQ Score currently favors AXGN over BAC, 65 versus 56 as of Nov 18, 2026. AXGN's advantage is driven primarily by stronger momentum and quality, while BAC holds the stronger value profile. AXGN also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors BAC. 3 of 6 covered evidence groups favor AXGN today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. AXGN lead: Reversed — BAC led by 6 AIQ points 30 sessions ago; AXGN now leads by 9.

Compare AxoGen, Inc. and Bank of America Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

AXGN
+463.3%
BAC
+19.5%

Total return comparison

Growth of $10,000, distributions reinvested

AXGN $56,330 · BAC $11,945

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare AXGN and BAC against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AXGN advantage
0
BAC advantage
  • Momentum82 vs 34
    AXGN +48
  • Value33 vs 65
    BAC +32
  • Risk Resilience55 vs 83
    BAC +28
  • Quality70 vs 64
    AXGN +6

3 of 6 evidence groups favor AXGN. AXGN’s edge is concentrated in momentum and quality; BAC keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

AXGN+3 AIQ

Largest factor move: Momentum +8

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.66x)
BAC-1 AIQ

Largest factor move: Value -3

New signals

  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)

AXGN's lead widened by 4 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — AXGN and BAC both carry a full feed there.

The central trade-off

AXGN (AxoGen, Inc.): the stronger current systematic profile, led by momentum and quality.

BAC (Bank of America Corporation): the counter-case, on value, risk resilience, valuation.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

AXGN

AXGN on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

AXGN

AXGN on combined revenue and EPS growth.

Value

BAC

BAC on the peer-relative Value factor, by 32 points.

Momentum

AXGN

AXGN on the Momentum factor, by 48 points.

Lower downside

BAC

BAC on Risk Resilience, by 28 points.

Analyst upside

BAC

BAC on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors AXGN, analyst targets favor BAC. That disagreement is the most useful thing on this page.

MeasureAXGNBACNote
Implied upside to target+2.1%+29.4%BAC has more room
Target dispersion+20.6%+25.3%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1125Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor AXGN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreAXGN65 vs 56
FundamentalsAXGNon balancerevenue growth 8.8% vs -3.3%; EPS growth 233.3% vs -23.8%; TTM ROE 0.5% vs 2.3%; gross margin 74.2% vs 60.4%; operating margin -5.2% vs 22.4% — AXGN takes 3 of 5 decided legs, not all of them
ValuationBACValue 33 vs 65
TechnicalsAXGNPrice vs 50-day 31.6% vs -9.5%; vs 200-day 38% vs -7%
Risk ResilienceBACRisk Resilience 55 vs 83
Analyst expectationsBACTarget upside 2.1% vs 29.4%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AXGN and BAC and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 9 points.
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AXGN.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

AXGN lead: Reversed — BAC led by 6 AIQ points 30 sessions ago; AXGN now leads by 9.

Jun 1AXGN leads above the line · BAC leads belowNov 18
Today
AXGN +9
65 vs 56
7 sessions ago
AXGN +4
62 vs 58
30 sessions ago
BAC +6
56 vs 62
90 sessions ago
BAC +6
64 vs 70

The lead changed hands once in this window, most recently on Nov 4 when AXGN moved ahead of BAC.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AXGNConflicted

5 bullish / 1 bearish / 2 neutral, conflicted

Only AXGN

  • Golden Cross Active — bullish, trend, long horizon (6.76%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.29%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Keltner Channel Breakout — bullish, volatility, short horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.66x)
  • TRIX Bullish Signal — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon
BACConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BAC

  • Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
  • Death Cross Active — bearish, trend, long horizon (1.45%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)

AXGN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AXGNConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +2.85%, AIQ +3 points).

BACConfirmed weakness

Price and the AIQ Score both moved down over the latest session (price -1.07%, AIQ -1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BAC closes the Momentum gap — currently 48 points behind, the largest single contributor to AXGN's edge.
  2. 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3AXGN's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

AXGN leads on balance
MetricAXGNBAC
Revenue growth (YoY)8.8%-3.3%
EPS growth (YoY)233.3%-23.8%
Gross margin74.2%60.4%
Operating margin-5.2%22.4%
Return on equity (TTM)0.5%2.3%
Debt to equity0.041.28

Performance

AXGN leads 6 of 6 windows
MetricAXGNBAC
1 week (5 sessions)11.8%3.2%
1 month (20 sessions)61.6%-0.4%
3 months (63 sessions)13.8%-20.1%
6 months (126 sessions)36.4%2.5%
Year to date70.9%-7.2%
1 year (252 sessions)132.2%-5.7%

Technicals

AXGN has the stronger structure
MetricAXGNBAC
RSI (14)69.945.9
ADX (14)41.927.2
Price vs 50-day31.6%-9.5%
Price vs 200-day38%-7%
Volatility (1M, annualized)125.5%24.8%

Risk

BAC is the more resilient
MetricAXGNBAC
Beta1.090.79
Sharpe ratio1.61-0.22
Sortino ratio2.99-0.29
Max drawdown-33.1%-23.7%
Current drawdown-4.6%-21.3%
Annualized volatility61.3%22.4%
Value at risk (95%)-5%-2.6%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AXGN or BAC?

On the Algovestiq AIQ Score, AXGN is the stronger of the two as of Nov 18, 2026, scoring 65 against BAC's 56. The edge comes from momentum and quality. BAC is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AXGN or BAC the better buy right now?

AXGN carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor AXGN over BAC?

The composite weights Quality, Value, Momentum and Risk Resilience. AXGN leads Momentum by 48 points; BAC leads Value by 32 points; BAC leads Risk Resilience by 28 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, AXGN or BAC?

Analyst price targets imply +2.1% upside for AXGN and +29.4% for BAC, so the Street currently favors BAC. That points the opposite way to the AIQ Score, which favors AXGN. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AXGN or BAC?

BAC is the better-valued of the two on the peer-relative Value factor. BAC on the peer-relative Value factor, by 32 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AXGN or BAC?

AXGN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AXGN or BAC?

AXGN on the Momentum factor, by 48 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AXGN or BAC?

BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 28 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AXGN more profitable than BAC?

The profitability evidence is mixed: gross margin 74.2% vs 60.4%; operating margin -5.2% vs 22.4%; ttm roe 0.5% vs 2.3%. AXGN leads on one measure and BAC on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is AXGN's lead over BAC getting stronger or weaker?

AXGN lead: Reversed — BAC led by 6 AIQ points 30 sessions ago; AXGN now leads by 9. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has changed hands once in that window, most recently on 2026-11-04, when AXGN moved ahead of BAC.

What would change the AXGN vs BAC verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 48 points behind, the largest single contributor to AXGN's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; AXGN's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about AXGN and BAC?

AXGN: 5 bullish / 1 bearish / 2 neutral, conflicted. BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AXGN is Golden Cross Active (bullish, long horizon). On BAC it is Death Cross Active (bearish, long horizon).

Compare AXGN and BAC with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.